News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZS Pharma Announces Start Of Enrollment Of Phase 3 Extended Dosing Study Of ZS-9 In Patients With Hyperkalemia


3/25/2014 9:43:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. This randomized, double-blind, placebo-controlled study is designed to confirm, over a longer treatment period, the positive results previously reported for ZS003, a Phase 3 trial in which a once-daily dose of ZS-9 (5g or 10g) maintained potassium levels within the normal range with safety and tolerability similar to placebo.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
ZS Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES